|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Gambro_AB
gptkb:Merck_KGa_A's_biosimilars_business
Rhoen-Klinikum AG
B. Braun's infusion business
|
|
gptkbp:ceo
|
Rice Powell
|
|
gptkbp:competitors
|
gptkb:Abbott_Laboratories
gptkb:Baxter_International
gptkb:Medtronic
gptkb:Da_Vita_Inc.
B. Braun
|
|
gptkbp:employees
|
around 300,000
|
|
gptkbp:founded
|
1912
|
|
gptkbp:founder
|
Carl Friedrich Fresenius
|
|
gptkbp:global_presence
|
operates in over 100 countries
|
|
gptkbp:head
|
gptkb:Fresenius_Group
gptkb:Fresenius_Kabi
gptkb:Fresenius_Medical_Care
Fresenius Helios
Fresenius Vamed
|
|
gptkbp:headquarters
|
Bad Homburg vor der Höhe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fresenius SE & Co. KGa A
|
|
gptkbp:ibu
|
DE0005785604
|
|
gptkbp:industry
|
healthcare
|
|
gptkbp:market_cap
|
around 20 billion EUR (2021)
|
|
gptkbp:market_segment
|
hospital management
nutrition market
dialysis market
infusion therapy market
|
|
gptkbp:parent_company
|
gptkb:Fresenius_Group
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Boehringer_Ingelheim
gptkb:Baxter_International
gptkb:Pfizer
gptkb:Novartis
|
|
gptkbp:products
|
clinical nutrition
dialysis products
hospital management services
infusion solutions
|
|
gptkbp:research_and_development
|
invests heavily in R& D
|
|
gptkbp:revenue
|
36.4 billion EUR (2020)
|
|
gptkbp:social_responsibility
|
engages in corporate social responsibility initiatives
|
|
gptkbp:stock_exchange
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Fresenius_Kabi
gptkb:Fresenius_Medical_Care
Fresenius Helios
Fresenius Vamed
|
|
gptkbp:sustainability
|
focuses on sustainable practices
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.fresenius.com
|
|
gptkbp:bfsParent
|
gptkb:Fresenius_Kabi
|
|
gptkbp:bfsLayer
|
6
|